Articles related to CHEMOTHERAPY

Initial results of the PREOPANC trial — comparing the addition of neoadjuvant chemoradiation therapy of gemcitabine combined plus Gy radiotherapy to standard care — failed to demonstrate a statistically significant overall survival (OS) improvement versus standard care of upfront surgery followed by adjuvant therapy. The long-term results, however, demonstrate significant benefit with neoadjuvant chemoradiation therapy consisted of gemcitabine combined plus Gy radiotherapy. The five year OS rate was 20.5% (95% CI, 14.2 to 29.8) with neoadjuvant chemoradiotherapy and 6.5% with upfront surgery.

This study reports long term outcomes on CALGB 40603 at a median follow-up of 7.9 years. Event-free survival and other LTOs were not significantly improved with either study drug overall or in studied sub-populations. Results showed that patients with any residual disease had significantly worse outcomes. This finding supports considering adjuvant therapy even in the setting of minimal residual disease.

This update of the GO29365 study shows significant survival benefit with pola + BR vs BR alone in R/R, transplant ineligible DLBCL. In the randomization arms, median progression-free survival was 9.2 vs 3.7 months and median overall survival was 12.4 vs 4.7 months for the pola + BR arm vs the BR arm. In the extension cohort, the OR rate was 41.5%, and the CR rate was 38.7%; PFS and OS were 6.6 months and 12.5 months, respectively.

This open-label, randomized phase II-III study of 191 patients with locally advanced or metastatic BTC compared triplet therapy of oxaliplatin, irinotecan, and infusional fluorouracil (mFOLFIRINOX), with doublet therapy consisting of cisplatin and gemcitabine (CISGEM). Triplet therapy did not outperform doublet therapy in this study.

The conclusion from the study presented in the Journal of Clinical Oncology: “While VTC added to five-drug interval compressed chemotherapy did not improve survival, these outcomes represent the best survival estimates to date for patients with previously untreated nonmetastatic Ewing sarcoma.”

Directly from this Journal of Clinical Oncology Original Report: “Among men randomly assigned to receive ADT + RT + docetaxel versus ADT + RT, significantly less RT-induced cancers were observed. The treatment effect of adding docetaxel to ADT + RT on overall survival in men with a prostate-specific antigen (PSA) < 4 ng/mL was driven by the absence of PC death, providing evidence to support a distinct biology in low PSA-producing, unfavorable-risk PC that is docetaxel-sensitive.”